Day: January 7, 2022

DALLAS, Jan. 07, 2022 (GLOBE NEWSWIRE) — Triumph Bancorp, Inc. (Nasdaq: TBK) today announced that it expects to release its fourth quarter and full year financial results after the market closes on Thursday, January 20, 2022. Upon filing, the financial results will be available on the Company’s website at www.triumphbancorp.com through the Investor Relations portal. Aaron P. Graft, Vice Chairman and CEO, and Brad Voss, CFO, will review the financial results in a conference call for investors and analysts beginning at 7:00 a.m. CST on Friday, January 21, 2022. To participate in the live conference call, please dial 1-844-200-6205 (International: +1-929-526-1599) and access code 984179. A simultaneous audio-only webcast may be accessed via the Company’s website at www.triumphbancorp.com through the Investor Relations, News...

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the completion of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. In addition, the underwriters have exercised in full their option to purchase an additional 1,428,571 shares. All of the shares in the offering were sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies of approximately $460.0 million and net proceeds of approximately $433.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. J.P. Morgan, SVB Leerink, BofA Securities,...

TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia Local Cryopreservation of Tumor Samples may Address Challenges of Longer Shipment Times and Broaden Global Access for TIL Therapy SAN CARLOS, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte (TIL) cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually. Details for the abstracts are as follows: Title: Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma...

MCLEAN, Va., Jan. 07, 2022 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) today published its first annual sustainability disclosure in accordance with standards issued by the Sustainability Accounting Standards Board (SASB). Freddie Mac primarily reported against relevant Mortgage Finance standards within the Financials sector, but also responded to relevant metrics pertaining to Commercial Banks and Investment Banking & Brokerages. The SASB disclosure provides data on Freddie Mac’s business practices, including metrics and activities related to equitable lending, flood risk and diversity in hiring for the year ended December 31, 2020. The report is available on the company’s newly created corporate environmental, social and governance (ESG) webpage, which outlines Freddie Mac’s approach to integrating ESG issues into its business...

SOUDERTON, Pa., Jan. 07, 2022 (GLOBE NEWSWIRE) — Univest Financial Corporation (Nasdaq: UVSP), parent company of Univest Bank and Trust Co. and its insurance, investment and equipment finance subsidiaries, announced it will host a conference call to discuss its fourth quarter and year end 2021 earnings on Thursday, January 27, 2022 at 9:00 a.m. Earnings are scheduled to be released after the close of the market on Wednesday, January 26, 2022. Pre-registrationTelephone participants may avoid any delays by pre-registering for the call using the following link to receive a special dial-in number and PIN. Conference Call registration link:https://www.incommglobalevents.com/registration/q4inc/9616/univest-financial-corporation-to-hold-fourth-quarter-and-year-end-2021-earnings-call/ AudioDial in number: 1-844-200-6205Access Code: 454983Note:...

ATLANTA, Jan. 07, 2022 (GLOBE NEWSWIRE) — Atlantic Capital Bancshares, Inc. (Nasdaq: ACBI) announces today that it will release fourth quarter financial results on Monday, January 24, 2022, after the market closes.   About Atlantic CapitalAtlantic Capital Bancshares, Inc. (ACBI), with assets of $4.2 billion, is a publicly-traded bank holding company headquartered in Atlanta, Georgia. Atlantic Capital offers commercial and not-for-profit banking services, specialty corporate financial services, private banking services and commercial real estate finance solutions to privately held companies and individuals in the Atlanta area, as well as specialized financial services for select clients nationally. Investor Relations:Patrick T. OakesExecutive Vice PresidentChief Financial OfficerEmail: Patrick.oakes@atlcapbank.comPhone: 404.995.6050 Corporate...

NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 – 13, 2022. 40th Annual J.P. Morgan Healthcare ConferenceDate:  Thursday, January 13th, 2022   Time: 9:45am Eastern Time   Webcast: The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com About Immunovant, Inc.  Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases....

WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), have been selected for a poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (“ASTCT”) and Center for International Blood & Marrow Transplant Research (“CIBMTR”), taking place February 2 – 6, 2022...

TORONTO, Jan. 07, 2022 (GLOBE NEWSWIRE) — (TSX: LCS, LCS.PR.A) Brompton Lifeco Split Corp. (the “Company”) is pleased to announce a successful overnight treasury offering of class A shares and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively). Gross proceeds of the offering are expected to be approximately $40.5 million. The offering is expected to close on or about January 13, 2022 and is subject to certain closing conditions. The Company has granted the Agents (as defined below) an over-allotment option, exercisable for 30 days following the closing date of the offering, to purchase up to an additional 15% of the number of Class A Shares and Preferred Shares issued at the closing of the offering. The Class A Shares were offered at a price of $6.95 per Class A Share for a distribution rate of 12.9% on...